LGR5 is a biomarker for stratification of HER-2 positive breast cancer patients and personalized treatment |
| |
| Authors: | Chan Chen Cheng Zhang Jun-Mei Xu Yong Han |
| |
| Affiliation: | 1. Department of Anesthesiology, Second Xiangya Hospital, Central South University, Anesthesiology Research Institute, Central South University, Changsha, Hunan, China;2. Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China;3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, United States |
| |
| Abstract: | ![]()
VEGFR and HER2 are both important transmembrane proteins associated with several types of cancer. Overexpression of these 2 proteins had long been thought to contribute to cancer progression and poor outcomes, thus, therapies targeting HER-2 and VEGFA signaling pathways have been applied in recent years. |
| |
| Keywords: | AKT, v-akt murine thymoma viral oncogene CTNNB1, catenin (cadherin-associated protein), beta 1 HER-2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 IgG1, immunoglobulin G 1 LGR5, leucine-rich repeat containing G protein-coupled receptor 5 MAPK, mitogen-activated protein kinase P27, cyclin-dependent kinase inhibitor 1B (p27, Kip1) PI3K, phosphoinositide-3-kinase PTEN, phosphatase and tensin homolog RER, rough endoplasmic reticulum VEGFA, vascular endothelial growth factor A VEGFR, vascular endothelial growth factor receptor |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
